期刊
CELL METABOLISM
卷 26, 期 2, 页码 343-+出版社
CELL PRESS
DOI: 10.1016/j.cmet.2017.07.011
关键词
-
资金
- AbbVie
- AstraZeneca
- Boehringer Ingelheim
- BMS
- Elcelyx
- Eli Lilly Co.
- Ionis
- Janssen
- Johnson and Johnson
- Ligand
- Merck
- Mylan
- Novartis
- Novo Nordisk
- Pfizer
- Sanofi
- Theracos
- vTv
Unimolecular dual incretins derived from hybridized glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) sequences have demonstrated synergistic reduction of adiposity in animal models and reductions of hyperglycemia in short-duration human trials. Here, we extend the characterization of NNC0090-2746 (also known as RG7697), a fatty-acylated dual agonist possessing in vitro balanced GIPR and GLP-1R agonism. In this 12-week, randomized, placebo-controlled, double-blind phase 2a trial, patients with type 2 diabetes inadequately controlled with metformin received 1.8 mg of NNC0090-2746 or placebo subcutaneously once daily. Liraglutide 1.8 mg (Victoza), starting with 2-week dose escalation, was administered subcutaneously once daily as an open-label reference arm. Measurements were collected at regular intervals after randomization. NNC0090-2746 significantly improved glycemic control and reduced body weight compared with placebo. Total cholesterol, alone among a range of lipid parameters, and leptin were both significantly reduced compared with placebo. Treatment with NNC0090-2746 was generally safe and well tolerated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据